PASSAGE BIO INC's ticker is PASG and the CUSIP is 702712100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,661,971 | -30.1% | 10,124,576 | 0.0% | 0.14% | -17.9% |
| Q2 2023 | $9,530,263 | +11.4% | 10,124,576 | +13.4% | 0.17% | +3.0% |
| Q1 2023 | $8,554,175 | -30.6% | 8,931,999 | 0.0% | 0.17% | -28.8% |
| Q4 2022 | $12,326,159 | +10.4% | 8,931,999 | 0.0% | 0.24% | +14.0% |
| Q3 2022 | $11,165,000 | -47.0% | 8,931,999 | 0.0% | 0.21% | -45.8% |
| Q2 2022 | $21,080,000 | -7.3% | 8,931,999 | +21.8% | 0.38% | +3.5% |
| Q1 2022 | $22,729,000 | -48.6% | 7,331,999 | +5.3% | 0.37% | -35.0% |
| Q4 2021 | $44,214,000 | -36.2% | 6,962,899 | 0.0% | 0.57% | -25.5% |
| Q3 2021 | $69,350,000 | -24.8% | 6,962,899 | 0.0% | 0.76% | -18.2% |
| Q2 2021 | $92,189,000 | -24.3% | 6,962,899 | 0.0% | 0.93% | -18.1% |
| Q1 2021 | $121,711,000 | -31.6% | 6,962,899 | 0.0% | 1.14% | -27.0% |
| Q4 2020 | $178,041,000 | +95.0% | 6,962,899 | 0.0% | 1.56% | +35.8% |
| Q3 2020 | $91,284,000 | -52.0% | 6,962,899 | 0.0% | 1.15% | -57.2% |
| Q2 2020 | $190,296,000 | +73.5% | 6,962,899 | 0.0% | 2.68% | +45.4% |
| Q1 2020 | $109,666,000 | – | 6,962,899 | – | 1.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 4,959,769 | $4,668,631 | 5.54% |
| New Leaf Venture Partners, L.L.C. | 2,497,922 | $2,348,047 | 2.02% |
| BML Capital Management, LLC | 2,058,767 | $1,937,917 | 1.74% |
| Lynx1 Capital Management LP | 1,167,343 | $1,098,820 | 0.72% |
| Acuitas Investments, LLC | 418,173 | $393,626 | 0.23% |
| Orbimed Advisors | 10,124,576 | $9,530,263 | 0.17% |
| Frazier Life Sciences Management, L.P. | 1,850,000 | $1,741,405 | 0.10% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $282,390 | 0.04% |
| Marquette Asset Management, LLC | 86,050 | $80,999 | 0.02% |
| Annandale Capital, LLC | 54,338 | $51 | 0.02% |